Home Medical Equipment & Post-Acute Respiratory Care
Strategic Profile
Leadership in in-home ventilation and rapid growth in complementary services strengthen revenue mix and improve margins, while acquisitions, regulatory tailwinds, and tech investments support geographic expansion and position the company for stable, diversified long-term growth. The company leverages clinical expertise and infrastructure to serve a growing population of post-acute respiratory patients.
Cyborg Score Rationale
Viemed demonstrates leadership in in-home ventilation with strengthening revenue mix and improving margins. However, the company faces market headwinds with mixed recent performance and scaling execution risks in an increasingly competitive respiratory care sector.
Top Insights
Company provides neuromuscular care, oxygen therapy services, and sleep apnea management with PAP and related equipment solutions.
Accelerated recruiting and refined sales force focusing on ventilator growth are set to boost revenue through increased ventilator setups.
Company offers in-home sleep apnea testing services and healthcare staffing and recruitment services.
Stock trading at $7.24 with market cap near $281M and analyst 1-year target of $13.00, suggesting 80%+ upside potential.
Named Competitors
Oxygen Concentrators and CPAP Equipment — Large diversified medical device manufacturer with respiratory product lines
In-Home Respiratory Care Services — Larger home healthcare providers offering respiratory management services
Sleep Apnea and Respiratory Equipment — Global digital health leader in cloud-connected respiratory care devices